No CrossRef data available.
Article contents
Academic psychiatry and the pharmaceutical industry: useful partnership or dangerous interaction?
Published online by Cambridge University Press: 18 May 2011
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Editorials
- Information
- Copyright
- Copyright © Cambridge University Press 2007
References
REFERENCES
Adams, C. & Jayaram, M. (2007). Do findings from new trials for schizophrenia fit with existing evidence: not duped just beguiled? Epidemiologia e Psichiatria Sociale 16, 199–202.Google Scholar
Barbui, C. & Cipriani, A. (2007). Evidence-based psychopharmacology: an agenda for the future. Evidence Based Mental Health 10, 4–6.Google Scholar
Barbui, C. & Garattini, S. (2007). Regulatory policies on medicines for psychiatric disorders: is Europe on target? British Journal of Psychiatry 190,91–93.Google Scholar
Healy, D. (2007). The engineers of human souls & academia. Epidemiologia e Psichiatria Sociale 16, 205–211.Google Scholar
Moncrieff, J. (2007). Co-opting psychiatry: the alliance between academic psychiatry and the pharmaceutical industry. Epidemiologia e Psichiatria Sociale 16, 192–196.Google Scholar
Pilling, S. & Price, K. (2006). Developing and implementing clinical guidelines: lessons from the NICE Schizophrenia Guideline. Epidemiologia e Psichiatria Sociale 15, 109–116.Google Scholar
Tognoni, G. & Franzosi, M.G. (2005). [Experimenting in Italy: from GIS-SI to the Ministerial Decree]. Recenti Progressi in Medicina 96, 92–94.Google Scholar
Tohen, M. (2007). Collaborations between academic psychiatry and the pharmaceutical industry: A perspective from industry. Epidemiologia e Psichiatria Sociale 16, 197–198.Google Scholar
You have
Access